{"contentid": 488282, "importid": NaN, "name": "Rebranded Hutchmed secures $100 million investment", "introduction": "Hutchison China MediTech, also known as Hutchmed, has announced a private placement of $100 million of funds from Baring Private Equity Asia (BPEA).", "content": "<p>Hutchison China MediTech (Nasdaq: HCM), also known as Hutchmed, has announced a private placement of $100 million of funds from Baring Private Equity Asia (BPEA).</p>\n<p>Hutchmed is listed on the Nasdaq stock exchange in New York and the London Stock Exchange&rsquo;s AIM market.</p>\n<p>Commenting on the placement, BPEA chief executive Jean Eric Salata said: &ldquo;The healthcare sector in China is a core area of investment focus,&rdquo; adding the firm &ldquo;looks forward to working with the CEO and management team to support the company&rsquo;s innovation and global growth aspirations.&rdquo;</p>\n<h2>Hutchmed progress</h2>\n<p>Headquartered in Hong Kong, the company has recently consolidated its identity under the Hutchmed brand.</p>\n<p>The biotech was formerly known as Chi-Med, with the brand Hutchison MediPharma reserved for novel R&amp;D operations in oncology.</p>\n<p>The company is pursuing an in-house drug discovery strategy, drawing from an R&amp;D program which has produced 10 clinical-stage drug candidates and a further seven late-stage preclinical assets over the past fifteen years.</p>\n<p>Focused on oncology and immunology, the company has built a sales and marketing operation in its core US and Chinese markets with around 1,200 personnel.</p>\n<p>Hutchmed is now looking to accelerate sales for its first two oncology drugs, Elunate (fruquintinib) in metastatic colorectal cancer, and the recently-launched Sulanda (surufatinib) in neuroendocrine tumors.</p>\n<p>Chief executive Christian Hogg said he expected &ldquo;significant growth of our business this year,&rdquo; including &ldquo;the potential upcoming approval of savolitinib, likely to be a first-in-class selective c-MET inhibitor in China.&rdquo;</p>\n<p>In a statement, the firm said it was planning to initiate up to 10 registration and registration-intent studies in 2021.</p>", "date": "2021-04-08 11:38:00", "meta_title": NaN, "meta_keywords": "Hutchmed, private, million, China, company, placement, BPEA, Hutchison, London, Rebranded, launch, MediTech, funds, announced, Baring, Equity, Asia, Nasdaq", "meta_description": "Hutchison China MediTech, also known as Hutchmed, has announced a private placement of $100 million of funds from Baring Private Equity Asia (BPEA).", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-08 11:14:35", "updated": "2021-04-09 09:28:28", "access": NaN, "url": "https://www.thepharmaletter.com/article/rebranded-hutchmed-to-launch-in-london-with-100-million", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "hutchmed_big.jpg", "image2id": "hutchmed_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immunologicals, Oncology", "topic_tag": "Business Financing, Management, Research", "geography_tag": "China, UK", "company_tag": "Chi-Med, Hutchison China MediTech, Hutchmed", "drug_tag": "Elunate, Sulanda", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-08 11:38:00"}